New technology also can be used to turn off peanut and other food allergies
In an entirely new approach to treating asthma and allergies, a biodegradable nanoparticle acts like a Trojan horse, hiding an allergen in a friendly shell, to convince the immune system not to attack it, according to new Northwestern Medicine research. As a result, the allergic reaction in the airways is shut down long- term and an asthma attack prevented.
The technology can be applied to food allergies as well. The nanoparticle is currently being tested in a mouse model of peanut allergy, similar to food allergy in humans.
“The findings represent a novel, safe and effective long-term way to treat and potentially ‘cure’ patients with life-threatening respiratory and food allergies,” said senior author Stephen Miller, the Judy Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine. “This may eliminate the need for life-long use of medications to treat lung allergy.”
It’s the first time this method for creating tolerance in the immune system has been used in allergic diseases. The approach has been used in autoimmune diseases including multiple sclerosis and celiac disease in previous preclinical Northwestern research.
The asthma allergy study was in mice, but the technology is progressing to clinical trials in autoimmune disease. The nanoparticle technology is being developed commercially by Cour Pharmaceuticals Development Co., which is working with Miller to bring this new approach to patients. A clinical trial using the nanoparticles to treat celiac disease is in development.
The new study on nanoparticles treating asthma was published April 18 in the Proceedings of the National Academy of Sciences.
“It’s a universal treatment,” Miller said. “Depending on what allergy you want to eliminate, you can load up the nanoparticle with ragweed pollen or a peanut protein.”
The nanoparticles are composed of an FDA-approved biopolymer called PLGA that includes lactic acid and glycolic acid.
Also a senior author is Lonnie Shea, adjunct professor of chemical and biological engineering at Northwestern’s McCormick School of Engineering and of obstetrics and gynecology at Feinberg, and chair of biomedical engineering at the University of Michigan.
When the allergen-loaded nanoparticle is injected into the bloodstream of mice, the immune system isn’t concerned with it because it sees the particle as innocuous debris. Then the nanoparticle and its hidden cargo are consumed by a macrophage, essentially a vacuum-cleaner cell.
“The vacuum-cleaner cell presents the allergen or antigen to the immune system in a way that says, ‘No worries, this belongs here,’” Miller said. The immune system then shuts down its attack on the allergen, and the immune system is reset to normal.
The allergen, in this case egg protein, was administered into the lungs of mice who have been pretreated to be allergic to the protein and already had antibodies in their blood against it. So when they were re-exposed to it, they responded with an allergic response like asthma. After being treated with the nanoparticle, they no longer had an allergic response to the allergen.
The approach also has a second benefit. It creates a more normal, balanced immune system by increasing the number of regulatory T cells, immune cells important for recognizing the airway allergens as normal. This method turns off the dangerous Th2 T cell that causes the allergy and expands the good, calming regulatory T cells.
The Latest on: Nanoparticles asthma allergies
via Google News
The Latest on: Nanoparticles asthma allergies
- Novel molecules to combat asthma and covid-related lung diseases discoveredon January 25, 2021 at 8:02 am
PCS travels all the way from the gut, to the lungs, and acts on epithelial cells lining the airways to prevent the allergic asthma response" The researchers also tested the metabolites in animal ...
- Nanoparticles in Targeted Cancer Therapyon January 20, 2021 at 4:00 pm
Recent preclinical data highlights mesoporous silica nanoparticles (MSNs) as a safe, biocompatible technology platform for targeted drug delivery. Silica-based nanoparticles C-dots were recently ...
- Food Allergies Be Gone: Nanoparticles Call for an Immune Ceasefireon January 19, 2021 at 10:57 am
The scientists performed a series of experiments in a mouse model of egg allergy. When the mice were exposed to egg proteins, they would display asthma-like symptoms such as difficulty breathing.
- Nasal Polyps Treatment Market Size, Competitive Strategies, Application Analysis, Regional, and Forecasts 2020 To 2030on January 19, 2021 at 6:43 am
They are the resultant of the chronic inflammation and are usually related to asthma, allergies, recurring infection, certain immune disorders, and drug sensitivity. The smaller nasal polyps do ...
- In lab study, nanoparticle shows promising results for treating severe allergieson January 15, 2021 at 7:12 am
“Normally, asthma and anaphylaxis are treated with an ... mice that were pretreated with injections of the nanoparticle containing the entire egg protein and allergic mice pretreated with injections ...
- In lab study, nanoparticle shows promising results for treating severe allergieson January 15, 2021 at 6:25 am
For about one in 13 children in the U.S., normally harmless foodstuffs such as milk, eggs and peanuts can send the body's natural defenses into overdrive.
- In lab study, nanoparticle shows promising results for treating severe allergieson January 14, 2021 at 8:07 am
The mice were then sensitized to an egg protein in a way that would cause it to trigger asthma-like ... the liver-targeting nanoparticle containing the egg allergen generated regulatory T cells that ...
- Nanoparticle vaccine for COVID-19on January 8, 2021 at 10:37 am
Their vaccine, detailed in a paper published Jan. 5 in ACS Central Science, contains nanoparticles studded with the same proteins that comprise the virus's distinctive surface spikes. In addition ...
- Pfizer's vaccine raises allergy concernson December 31, 2020 at 5:51 pm
Severe allergy-like reactions in at least 12 people who received the COVID-19 vaccine produced by Pfizer and BioNTech may be due to a compound in the packaging of the messenger RNA (mRNA) that forms ...
via Bing News